Cat.No：GM-87982MAB
Product：Anti-CD40L hIgG1 Reference Antibody (Frebio)
Cat.No：GM-87982MAB
Product：Anti-CD40L hIgG1 Reference Antibody (Frebio)
GM-87982MAB-1mg / 1 mg
GM-87982MAB-5mg / 5 mg
GM-87982MAB-25mg / 5 mg * 5 vials
GM-87982MAB-50mg / 50 mg
GM-87982MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | CD40L |
Clone | Frexalimab |
Alternative Names | CD154, CD40LG, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L |
Source/Isotype | Monoclonal human IgG1(A215V E269R K322A), Kappa |
Application | Flow cytometry; Bioactivity-ELISA |
Description | IL-31RA (Interleukin-31 receptor α) gene encodes the specific receptor for interleukin-31 (IL-31). IL-31 is a cytokine secreted by immune cells such as Th2 cells, playing a critical role in regulating immune responses and inflammation, particularly in the skin immune microenvironment and neuro-immune interactions. It binds to the heterodimeric receptor formed by IL-31RA and IL-31RB, activating the JAK1/STAT3 signal transduction pathway, driving Th2-type inflammatory responses and mediating pathological processes such as itching. Frexalimab, a humanized monoclonal antibody, specifically targets IL-31RA by binding with high affinity to its extracellular epitope, blocking the interaction between the IL-31 cytokine and its receptor, thereby inhibiting downstream pro-inflammatory signaling. This mechanism can significantly alleviate Th2- type immune-mediated inflammatory responses, such as skin redness, exudation, and severe itching in atopic dermatitis (AD), as well as eosinophilic infiltration and mucus hypersecretion in asthma. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
Cat.No：GM-87982MAB
Product：Anti-CD40L hIgG1 Reference Antibody (Frebio)
GM-87982MAB-1mg / 1 mg
GM-87982MAB-5mg / 5 mg
GM-87982MAB-25mg / 5 mg * 5 vials
GM-87982MAB-50mg / 50 mg
GM-87982MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | CD40L |
Clone | Frexalimab |
Alternative Names | CD154, CD40LG, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L |
Source/Isotype | Monoclonal human IgG1(A215V E269R K322A), Kappa |
Application | Flow cytometry; Bioactivity-ELISA |
Description | IL-31RA (Interleukin-31 receptor α) gene encodes the specific receptor for interleukin-31 (IL-31). IL-31 is a cytokine secreted by immune cells such as Th2 cells, playing a critical role in regulating immune responses and inflammation, particularly in the skin immune microenvironment and neuro-immune interactions. It binds to the heterodimeric receptor formed by IL-31RA and IL-31RB, activating the JAK1/STAT3 signal transduction pathway, driving Th2-type inflammatory responses and mediating pathological processes such as itching. Frexalimab, a humanized monoclonal antibody, specifically targets IL-31RA by binding with high affinity to its extracellular epitope, blocking the interaction between the IL-31 cytokine and its receptor, thereby inhibiting downstream pro-inflammatory signaling. This mechanism can significantly alleviate Th2- type immune-mediated inflammatory responses, such as skin redness, exudation, and severe itching in atopic dermatitis (AD), as well as eosinophilic infiltration and mucus hypersecretion in asthma. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
